PURPOSE: Sclerostin, secreted by osteocytes, plays a key role in antagonizing bone formation. Recent studies, which seldom include chronic kidney disease (CKD) patients, have reported on the association of sclerostin and mortality, with contradictory results. The assay-linked variability may contribute to these discrepant results. METHODS: We have compared sclerostin results obtained with two assays (TECO and Biomedica) in a cohort of 91 CKD patients undergoing hemodialysis. RESULTS: We found a strong correlation (r = 0.870, p < 0.0001) between the serum sclerostin concentrations measured by the two assays. Bland-Altman plot shows that, although there was a partial agreement between the assays, differences found for individual values (-0.27 ± 0.54; ranging from -1.3 to 0.8 ng/ml) were quite unpredictable. By using TECO, there was a significant relationship between serum sclerostin, and calcitonin (r = 0.224), IL-6 (r = 0.251) and FGF23 (r = 0.331) levels while no correlation was found with PTH or total alkaline phosphatase. Regarding Biomedica, there was a significant correlation with calcitonin (r = 0.260), and β2 microglobulin (r = 0.210), but no correlation with PTH or total alkaline phosphatase. Overall, 25.3% among the patients had different classifications as to normal or high values, according to the manufacturer. CONCLUSION: Sclerostin levels should be interpreted with caution, as they can vary widely according to the assay used. Further studies are clearly needed before considering sclerostin as a true marker of mortality. Moreover, we do not know at present which serum sclerostin levels should be regarded as either normal or potentially dangerous in patients with CKD.
PURPOSE:Sclerostin, secreted by osteocytes, plays a key role in antagonizing bone formation. Recent studies, which seldom include chronic kidney disease (CKD) patients, have reported on the association of sclerostin and mortality, with contradictory results. The assay-linked variability may contribute to these discrepant results. METHODS: We have compared sclerostin results obtained with two assays (TECO and Biomedica) in a cohort of 91 CKDpatients undergoing hemodialysis. RESULTS: We found a strong correlation (r = 0.870, p < 0.0001) between the serum sclerostin concentrations measured by the two assays. Bland-Altman plot shows that, although there was a partial agreement between the assays, differences found for individual values (-0.27 ± 0.54; ranging from -1.3 to 0.8 ng/ml) were quite unpredictable. By using TECO, there was a significant relationship between serum sclerostin, and calcitonin (r = 0.224), IL-6 (r = 0.251) and FGF23 (r = 0.331) levels while no correlation was found with PTH or total alkaline phosphatase. Regarding Biomedica, there was a significant correlation with calcitonin (r = 0.260), and β2 microglobulin (r = 0.210), but no correlation with PTH or total alkaline phosphatase. Overall, 25.3% among the patients had different classifications as to normal or high values, according to the manufacturer. CONCLUSION:Sclerostin levels should be interpreted with caution, as they can vary widely according to the assay used. Further studies are clearly needed before considering sclerostin as a true marker of mortality. Moreover, we do not know at present which serum sclerostin levels should be regarded as either normal or potentially dangerous in patients with CKD.
Authors: Christiane Drechsler; Pieter Evenepoel; Marc G Vervloet; Christoph Wanner; Markus Ketteler; Nikolaus Marx; Jürgen Floege; Friedo W Dekker; Vincent M Brandenburg Journal: Nephrol Dial Transplant Date: 2014-09-23 Impact factor: 5.992
Authors: Bernhard O Bielesz; Till Hempfing; Heidi Kieweg; Rodrig Marculescu; Martin Haas; Daniel Cejka Journal: Blood Purif Date: 2014-09-13 Impact factor: 2.614
Authors: Flávia Letícia Carvalho Gonçalves; Rosilene M Elias; Luciene M dos Reis; Fabiana G Graciolli; Fernando Godinho Zampieri; Rodrigo B Oliveira; Vanda Jorgetti; Rosa M A Moysés Journal: BMC Nephrol Date: 2014-12-02 Impact factor: 2.388
Authors: Sebastian F Mause; Annika Deck; Mark Hennies; Nadine Kaesler; Pieter Evenepoel; William A Boisvert; Ulf Janssen; Vincent M Brandenburg Journal: Discoveries (Craiova) Date: 2016
Authors: Matthew T Drake; Jennifer S Fenske; Frank A Blocki; Claudia Zierold; Natasha Appelman-Dijkstra; Socrates Papapoulos; Sundeep Khosla Journal: Bone Date: 2018-03-14 Impact factor: 4.398
Authors: Geert J Behets; Liesbeth Viaene; Björn Meijers; Frank Blocki; Vincent M Brandenburg; Anja Verhulst; Patrick C D'Haese; Pieter Evenepoel Journal: PLoS One Date: 2017-05-11 Impact factor: 3.240
Authors: Mariel J Hernandez; Luciene M Dos Reis; Igor D Marques; Maria J Araujo; Cesar A M Truyts; Ivone B Oliveira; Fellype C Barreto; Elias David-Neto; Melani R Custodio; Rosa M Moyses; Ezequiel Bellorin-Font; Vanda Jorgetti Journal: PLoS One Date: 2018-05-25 Impact factor: 3.240
Authors: Isabelle Piec; Christopher Washbourne; Jonathan Tang; Emily Fisher; Julie Greeves; Sarah Jackson; William D Fraser Journal: Calcif Tissue Int Date: 2016-01-09 Impact factor: 4.333